>>> US and EU issue joint statement on a United States-European Union framework;

US and EU issue joint statement on a United States-European Union framework; European Union intends to eliminate tariffs on all U.S. industrial goods and to provide preferential market access; United States commits to apply the higher of either the U.S. Most Favored Nation tariff rate or a tariff rate of 15% (638.11)
  • "The European Union intends to eliminate tariffs on all U.S. industrial goods and to provide preferential market access for a wide range of U.S. seafood and agricultural goods, including tree nuts, dairy products, fresh and processed fruits and vegetables, processed foods, planting seeds, soybean oil, and pork and bison meat. The European Union will immediately take the necessary steps to extend the Joint Statement of the United States and the European Union on a Tariff Agreement announced on August 21, 2020, with respect to lobster (that expired 31 July 2025), coupled with an expanded product scope to include processed lobster.
  • The United States commits to apply the higher of either the U.S. Most Favored Nation tariff rate or a tariff rate of 15 percent, comprised of the MFN tariff and a reciprocal tariff, on originating goods of the European Union. Additionally, effective as of 1 September 2025, the United States commits to apply only the MFN tariff to the following products of the European Union: unavailable natural resources (including cork), all aircraft and aircraft parts, generic pharmaceuticals and their ingredients and chemical precursors. The United States and the European Union agree to consider other sectors and products that are important for their economies and value chains for inclusion in the list of products for which only the MFN tariffs would apply.
  • The United States intends to promptly ensure that the tariff rate, comprised of the MFN tariff and the tariff imposed pursuant to Section 232 of the Trade Expansion Act of 1962, applied to originating goods of the European Union subject to Section 232 actions on pharmaceuticals, semiconductors, and lumber does not exceed 15 percent. When the European Union formally introduces the necessary legislative proposal to enact the tariff reductions set forth in Section 1 of this Framework Agreement, the United States will reduce tariffs on automobiles and automobile parts originating from the European Union subject to Section 232 tariffs as follows: No Section 232 automobile or automobile parts tariffs will apply to covered European Union goods with an MFN tariff of 15 percent or higher; and for covered goods with an MFN rate lower than 15 percent, a combined rate of 15 percent, comprised of the MFN tariff and Section 232 automobile tariffs, will be applied. These tariff reductions are expected to be effective from the first day of the same month in which the European Union's legislative proposal is introduced. The United States expects the European Union's legislative proposals will be consistent with this Framework Agreement and enacted by the necessary legislatures. All modifications to U.S. Section 232 tariffs will be executed in a manner that reinforces and is consistent with U.S. national security interests. With respect to steel, aluminum, and their derivative products, the European Union and the United States intend to consider the possibility to cooperate on ring-fencing their respective domestic markets from overcapacity, while ensuring secure supply chains between each other, including through tariff-rate quota solutions.
  • The United States and the European Union commit to cooperate on ensuring secure, reliable, and diversified energy supplies, including by addressing non-tariff barriers that might restrict bilateral energy trade. As part of this effort, the European Union intends to procure U.S. liquified natural gas, oil, and nuclear energy products with an expected offtake valued at $750 billion through 2028. In addition, the European Union intends to purchase at least $40 billion worth of U.S. AI chips for its computing centers. The European Union further plans to work with the United States to adopt and maintain technology security requirements in line with those of the United States. in a concerted effort to avoid technology leakage to destinations of concern. The United States will endeavor to facilitate such exports once such requirements are in place.
  • The United States and the European Union commit to address unjustified digital trade barriers. In that respect, The European Union confirms that it will not adopt or maintain network usage fees. The United States and the European Union will not impose customs duties on electronic transmissions. The United States and the European Union intend to continue to support the multilateral moratorium on customs duties on electronic transmissions at the World Trade Organization and seek the adoption of a permanent multilateral commitment."
  • Release (related stocks: NUE, STLD, CLF, EADSY, BA, LMT, NOC, GD, LHX, VWAGY, BMWKY, STLA, MBGYY, ASML, SAP, XOM, CVX, LNG, VG, GLNG, OXY, DVN, CF, NTR, MOS, DE, DD, DOW, NVDA, MSFT, AMD, INTC, ARM, AVGO, TXN)

>>> Walmart misses by $0.05, reports revs in-line, U.S. comps (ex fuel) of +4.6

Walmart misses by $0.05, reports revs in-line, U.S. comps (ex fuel) of +4.6%; guides Q3 EPS above consensus; reaffirms FY26 EPS guidance (102.57)
  • Reports Q2 (Jul) earnings of $0.68 per share, $0.05 worse than the FactSet Consensus of $0.73; revenues rose 4.8% year/year to $177.4 bln vs the $175.94 bln FactSet Consensus.
  • Walmart U.S. Comp sales (ex fuel) of +4.6%.
  • Sam's Club U.S. comps (ex fuel) of +5.9%.
  • Global eCommerce sales grew 25%, led by store-fulfilled pickup & delivery and marketplace.
  • Global advertising business3 grew 46%, including VIZIO; Walmart Connect in the U.S. up 31%.
  • Gross margin rate up 4 bps, led by Walmart U.S.
  • Co issues upside guidance for Q3, sees EPS of $0.58-$0.60, excluding non-recurring items, vs. $0.57 FactSet Consensus. Sees net sales up 3.75-4.75% in constant currency.
  • Co reaffirms guidance for FY26, sees EPS of $2.52-$2.62, excluding non-recurring items, vs. $2.62 FactSet Consensus. Reaffirms net sales growth of 3.75-4.75% in constant currency

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • SCLX +17.3%, AEG +5.9%, NDSN +5.5%, INSG +4.3%, SVRA +3.2%, CRWV +2.6%, WRD +1.8%, ALVO +1.2%, ITRI +1.1%, UP +1%, HLX +0.9%, RYTM +0.8%
  • Gapping down:
    • COTY -21.4%, CSIQ -9%, HBNC -5.5%, AL -3.5%, TWO -2.9%, VNET -2.9%, SN -2.7%, BILI -2.7%, RJF -1.1%, BABA -0.8%

>>> US After Hours Summary: Quiet after hours session; NDSN +4.9% higher on earn

After Hours Summary: Quiet after hours session; NDSN +4.9% higher on earnings; COTY -15.6% lower on earnings; HBNC -8.1% lower on stock offering

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: NDSN +4.9% (also authorizes new $500 mln share repurchase program)

Companies trading higher in after hours in reaction to news: GAU +6.2% (drill results at Abore), INSG +4.3% (partnership with National MSP OneSource and launch of Janus), OII +1.4% (wins US Navy contract), CRWV +1.1% (Jane Street Group discloses 5.4% passive stake), DVA +0.5% (increases share repurchase program by $2 bln), DG +0.4% (names new CFO), YOU +0.1% (increases presence at Staples US retail stores), AL +0.1% (lease and delivery of 2 aircraft to China Airlines)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: COTY -15.6%

Companies trading lower in after hours in reaction to news: HBNC -8.1% (stock offering), TWO -3.8% (resolves Pine River litigation, lowers dividend), SN -2.7% (stock offering by selling shareholders; also mixed shelf), SVRA -1.9% (NEJM to publish results from Phase 3 IMPALA-2 trial), GILD -1.2% (CVS will not add GILD's new HIV prevention drug to its commercial plans, according to Reuters)

>>> VKTX - Comments on Phase 2 - Tolerability -ve --> -31%

.
VKTX (VK2735 oral, Ph2 VENTURE-Oral, 13w)
  • WL: -12.2% @13w (vs PBO -1.3%). ≥5% WL: 97%; ≥10% WL: 80%.
  • Negatives: High disc 28% (PBO 18%), AE-disc 20% (PBO 13%). GI-heavy (nausea 58%, vomit 26%) vs PBO (48%/10%). Daily pill → adherence risk. Only 13w data, durability unknown, no plateau yet. Exploratory high-dose cohort raises Qs on long-term titration.
LLY (Tirzepatide inj, SURMOUNT-1, 72w)
  • WL: -15% (5 mg) to -21% (15 mg).
  • AE-disc 4–7% (PBO 2.6%). Weekly inj.
NVO (Semaglutide inj “Wegovy”, STEP-1/others, 68–104w)
  • WL: ~-15% @68w, durable to 2y.
  • AE-disc ~6–7% (PBO ~3–4%). Weekly inj.
NVO (Oral sema 50mg, OASIS-1, 68w)
  • WL: -15.1% @68w (PBO -2.4%).
  • GI AEs 80% (PBO 46%). Daily pill. (AE-disc NR)
LLY (Orforglipron oral GLP-1, Ph2, 36w)
  • WL: -9.4% to -14.7%; AE-disc 10–17%.
  • Newer data: ~-12.4% @72w; ~10% AE-disc. Daily pill.

Read-through
  • VKTX efficacy headline competitive, but tolerability / disc rates are weak spots (28% vs mid-single digits for injectables; higher GI vs peers). Trial short (13w), durability unproven. Daily oral vs weekly injectors a compliance overhang.
  • Investors will want clarity on long-term safety, GI mitigation, and whether VKTX can match durability of LLY/NVO leaders.

VKTX : Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Tria

Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
- Announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. The Phase 2 VENTURE-Oral Dosing trial successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK2735 treatment to be safe and well-tolerated through 13 weeks of daily dosing with the majority of treatment emergent adverse events (TEAEs) being categorized as mild or moderate.Participants receiving once daily doses of the oral tablet formulation of VK2735 demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 12.2% from baseline. Participants receiving VK2735 also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to 10.9%. Reductions in body weight were progressive at all doses through the course of the study, with no plateau observed for weight loss at 13 weeks. Statistically significant differences compared to both baseline and placebo were observed for all doses >15 mg starting at Week 1 and continuing throughout the 13-week treatment period. All doses of VK2735 >15 mg also demonstrated statistically significant differences relative to placebo on the key secondary endpoint assessing the proportion of subjects demonstrating at least 5% and 10% weight loss. Up to 97% of subjects in the VK2735 treatment groups achieved ≥5% weight loss, compared with 10% for placebo, and up to 80% of subjects in VK2735 treatment groups achieved ≥10% weight loss, compared with 5% for placebo.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • FLXS +20.5%, IOVA +19.6%, WALD +16.1%, LIDR +14.2%, XYF +9.2%, GLSI +8.2%, PANW +6.3%, INTC +5.8%, FLEX +5.4%, CRNX +4.2%, SEG +3.3%, SNEX +3%, BHP +2.6%, RKLB +2.5%, TZUP +2.5%, DGII +2.1%, MD +1.9%, NEGG +1.7%, MDT +1.7%, CXW +1.6%, VSAT +1.5%, ALGN +1.2%, VALE +0.9%, NVO +0.9%, BNTX +0.8%
  • Gapping down:
    • FN -7.2%, EVH -4.7%, AGRO -4.5%, SFL -3.3%, ORIC -3.1%, AS -2.7%, XP -2.4%, API -2.3%, WULF -2.2%, TE -1.3%, RGNX -1.3%, TATT -1.2%, WDS -1%, PINC -0.9%

WSJ : Medtronic to Add Directors After Elliott Becomes Big Shareholder

Medtronic to Add Directors After Elliott Becomes Big Shareholder
The medical-device maker also plans to form committees focused on M&A and other growth areas

  • Elliott Investment Management is now one of Medtronic’s largest shareholders.
  • Medtronic plans to add two new directors and form two new committees after friendly talks with Elliott.
  • Medtronic is the largest med-tech company by revenue but is seen as undervalued compared with peers.

Medtronic MDT -0.23%decrease; red down pointing triangle is making changes to its board after Elliott Investment Management became one of its largest shareholders, according to people familiar with the matter.

The activist investor and the medical-device maker have been holding friendly talks around how to boost the company’s valuation and build on ongoing plans to focus on core assets.

The details
Medtronic plans to announce when it reports quarterly results Tuesday that veteran med-tech executives John Groetelaars and Bill Jellison are joining its board as independent directors, the people said. It will also detail the formation of new special committees focused on growth and operations that will include the new directors and be helmed by Medtronic Chief Executive Officer Geoff Martha.

Elliott is now one of Medtronic’s biggest investors, after an engagement led by Elliott partner Marc Steinberg, the people familiar with the matter said. The exact size of the firm’s previously undisclosed stake couldn’t be learned.

Medtronic develops, manufactures and distributes medical devices and therapies that treat more than 70 health conditions, from Parkinson’s to diabetes.

The company, which is based in Ireland but has its operational headquarters in Minneapolis, has a market value of almost $120 billion. Though its shares are up more than 16% so far this year, the company is still seen as undervalued, especially for being the biggest med-tech company globally by revenue.

Medtronic booked more than $32 billion in revenue in 2024. Boston Scientific, with a larger market value of almost $153 billion, reported about $17 billion in sales last year.

One of the new committees will look for so-called tuck-in M&A opportunities, research and development investments and potential divestitures. The other will look for ways to boost earnings growth, the people said.

Medtronic is also now set to host an Investor Day event in mid-2026, at which point the company expects to detail the new committees’ progress, the people said.

The context
Medical-device makers including Medtronic struggled coming out of Covid-19 to meet a rise in demand for procedures that people deferred during the pandemic, while also contending with inflationary pressures.

Medtronic faced additional challenges of its own, including those stemming from a 2021 warning letter from the Food and Drug Administration regarding product safety issues with its MiniMed insulin pumps. That matter has since been resolved.

Lately, Medtronic has focused its efforts on more recent innovations, for example around treating atrial fibrillation, which has been a huge growth spot in the industry. As part of efforts to simplify its portfolio, it planned a separation of its diabetes business into a stand-alone entity.

Elliott, known mostly for its work in tech and energy, has been increasingly active in the healthcare sector. Other investments have included contract drugmaker Catalent and Syneos Health.

>>> Europe : Brokers Upgrades & Downgrades - 19th of August 2025 V2(+)

>>> Up
* Assura Raised to Buy at Peel Hunt; PT 60 pence
* Aveanna Healthcare Raised to Overweight at Barclays; PT $9.50
* Caterpillar Raised to Outperform at Evercore ISI; PT $476
* Commerzbank PT Raised to 39 euros at Bankhaus Metzler (+)
* Gilead Raised to Outperform at Daiwa; PT $128
* IMI PT Raised to 2,850 pence from 2,500 pence at JPMorgan
* NN Group PT Raised to 75 euros from 70 euros at JPMorgan
* Orange Polska Raised to Outperform at Santander Biuro Maklerskie (+)
* Primary Health PT Raised to 120 pence at Peel Hunt
* Zalando Raised to Buy at Baader Helvea; PT 32 euros

>>> Down
* Aallon Group Cut to Accumulate at Inderes; PT 13 euros
* Anglogold Cut to Underweight at Nedbank CIB; PT $53.82
* Couche-Tard Cut to Market Perform at BMO; PT C$75
* Do & Co Cut to Hold at Wood & Company; PT 253 euros
* Dowlais Cut to Sector Perform at RBC; PT 77 pence
* Fresnillo Cut to Hold at Peel Hunt; PT 1,493 pence
* H&R Cut to Reduce at Baader Helvea; PT 5 euros
* Koskisen Cut to Reduce at Inderes; PT 9 euros
* Merck KGaA Cut to Equal-Weight at Barclays; PT 120 euros
* Pan African Cut to Underweight at Nedbank CIB; PT 54.53 pence
* TGS Cut to Hold at Fearnley; PT 65 kroner (+)
* THG PLC PT Cut to 24 pence from 28 pence at JPMorgan
* Torm Cut to Hold at Pareto Securities; PT 21 kroner (+)

>>> Initiation
* Cirsa Enterprises Rated New Buy at Rothschild & Co Redburn
* Cirsa Enterprises Rated New Buy at Deutsche Bank; PT 22.70 euros (+)
* Hugo Boss ADRs Rated New Underperform at BNPP Exane; PT $7.80 (+)
* Sats Rated New Buy at SEB Equities; PT 44 kroner
* Thermo Fisher Rated New Outperform at William Blair

>>> Call
* Metro Bank Mispriced Compared to Peers, RBC Raises to Outperform